EGFR and malignant colon neoplasm: Three CDx devices, Cobas EGFR Mutation Test V2, ONCO/Reveal Diagnostic Lung and Colon Cancer Assay, and FoundationOne CDx all received approval for therapeutic class labeling following the finalization and release of the April 2020 guidance reiterating the FDA’s position.